Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 5;22:301. doi: 10.1186/s12893-022-01752-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Changes in the blood test values of (a) WBC, (b) ALP, and (c) γ-GTP at the onset of post-PD cholangitis and after starting the initial treatment. Blood test results showed changes in the (a) white blood cell (WBC) counts, (b) alkaline phosphatase (ALP) levels, and (c) gamma-glutamyl transpeptidase (γ-GTP) values at the onset of post-pancreaticoduodenectomy cholangitis (PPDC) and after starting the initial treatment. For WBC counts, the median at the onset of PPDC and first blood test after starting treatment were 10,385 (range: 4120‒21,690) and 6000 (range: 2570‒17,260), respectively (a). The Wilcoxon signed-rank sum test for the two corresponding groups showed a statistically significant difference with P = 1.2 × 10^–6 (a). For ALP level, the median at the onset of PPDC and first blood test after starting treatment were 614 (range: 204‒2890) and 516 (range: 135‒2706), respectively (b). A statistically significant difference was noted among the two corresponding groups, with P = 3.2 × 10^–3 (b). For γ-GTP values, the median at the onset of PPDC and first blood test after starting treatment were 160 (range: 9‒1693) and 184 (range: 9‒1042), respectively (c). A statistically significant difference was noted among the two corresponding groups, with P = 0.016 (c)